20-F: BetterLife Pharma Reports Increased Losses Amidst Going Concern Doubts, Pursues Mental Health and Antiviral Drug Development

BetterLife Pharma Inc. reported a net loss of $3.62 million for the fiscal year ended January 31, 2025, increasing its accumulated deficit to over $118 million, raising substantial doubt about its ability to continue as a going concern.

Summary

• BetterLife Pharma Inc. incurred a net loss of $3,621,884 for the fiscal year ended January 31, 2025, an increase from $2,898,510 in the prior year.
• The company has not generated any revenue since its inception in June 2002 and has an accumulated deficit of $118,596,001 as of January 31, 2025.
• Operating expenses increased to $5,000,113 in fiscal 2025, primarily due to a significant increase in share-based payment expense, totaling approximately $2.05 million.
• The company reported a working capital deficiency of $7,313,034 as of January 31, 2025, an increase from $7,022,402 in the prior year.
• Cash used in operating activities was $2,021,752 for the year ended January 31, 2025.
• BetterLife is developing two neuro-psychiatric products: BETR-001 (a non-hallucinogenic LSD derivative for mental disorders) and BETR-002 (a dihydrohonokiol derivative for anxiety and benzodiazepine dependency).
• The company's subsidiary, MedMelior Inc., is developing MM-001 (a topical cream for HPV-induced Cervical Intraepithelial Neoplasia) and MM-003 (an inhaled interferon for respiratory viral infections).
• The company successfully concluded two significant legal claims, resulting in a financial guarantee recovery of approximately $759,000 and a gain from legal claim of approximately $557,000.
• Management has identified a material weakness in internal control over financial reporting due to the small size of its finance team and limited review controls for complex accounting transactions.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by increasing losses, a large accumulated deficit, negative cash flow from operations, and a significant working capital deficiency. The explicit 'going concern' warning and reliance on continuous financing for survival indicate a highly precarious financial position, despite some positive legal settlements and ongoing drug development efforts. The early stage of product development means no near-term revenue is expected, and significant risks remain.

Positives

• The company recorded a financial guarantee recovery of approximately $759,000 due to a lower judgment amount from the Superior Court of Quebec.
• A gain from legal claim of approximately $557,000 was recorded following the conclusion of claims against the company and its subsidiary MedMelior Inc. in State and Federal Courts without any payment or penalties.
• Accrued advisory fees of $107,904 to certain directors were forgiven in April 2024.
• Accrued compensation of $284,000 for certain officers was settled through the issuance of 1,893,333 common shares of MedMelior, reducing cash outflow.
• The company has developed a manufacturing process for BETR-001 that does not use LSD as a starting material, avoiding Schedule 1 controlled substance restrictions.
• MM-001 is considered clinical stage and has a US IND, with plans to file a new IND for Phase 2b studies using the company's own IFNa2b.

Negatives

• The company has not earned any revenue since its inception in June 2002.
• Net loss increased to $3,621,884 for the year ended January 31, 2025, from $2,898,510 in the prior year.
• Accumulated deficit reached $118,596,001 as of January 31, 2025.
• The company reported negative cash flows from operating activities of $2,021,752 for the year ended January 31, 2025.
• Working capital deficiency increased to $7,313,034 as of January 31, 2025.
• Operating expenses increased significantly to $5,000,113, driven by higher share-based payment expenses.
• Accretion and interest expense increased due to newly issued convertible debentures.
• The company's continued operations are dependent on its ability to generate future cash flows through additional financing or commercialization, indicating a material uncertainty about its going concern ability.
• The company's internal control over financial reporting was not effective as of January 31, 2025, due to a material weakness related to limited review controls for complex accounting transactions.

Risks

• Substantial doubt exists regarding the company's ability to continue operations, and if operations discontinue, investors could lose their entire investment.
• The company has incurred operating losses since inception and expects substantial and increasing losses for the foreseeable future, with no assurance of profitability even if products are commercialized.
• Significant additional funds are required to complete development and commercialization activities, and the unavailability of such funds could force the company to curtail or cease operations.
• Delays in completing development projects could lead to increased competition and delayed cash inflows from financial or partnership activities.
• Any pharmaceutical products developed will be subject to extensive governmental regulations (e.g., FDA), and there is no assurance of receiving regulatory approval.
• Failure to commence or complete clinical testing, or poor clinical strategy choices, could prevent the company from achieving revenues.
• Reliance on third parties for research, development, and manufacturing activities exposes the company to risks of non-performance, non-compliance with regulations, and intellectual property violations.
• Inability to establish a sales, marketing, and distribution infrastructure or secure collaborations could hinder product commercialization.
• Product candidates may never gain market acceptance, preventing revenue generation.
• Potential product liability exposure could divert resources, lead to product recalls, or terminate product sales.
• Ongoing regulatory requirements for manufacturing could lead to costly regulatory or enforcement actions.
• Limited ability for U.S. investors to enforce Canadian civil actions against directors located outside Canada.
• Indemnification of directors and officers could increase operating costs.
• Trading on OTCQB and CSE may be volatile and sporadic, depressing share price and making resale difficult.
• The company's stock is considered a 'penny stock,' which may limit a stockholder's ability to buy and sell shares due to SEC and FINRA regulations.
• Future financing efforts may result in dilution or subordinated stockholder rights, privileges, and preferences.
• The company does not intend to pay dividends, limiting ways for investors to gain from their investment to stock appreciation, which is not guaranteed.
• Inability to maintain and enforce proprietary intellectual property rights could prevent profitable operation.
• Intellectual property infringement claims could lead to substantial litigation expenses and potentially force the company out of business.
• Future requirements to license patent rights from third parties, which may not be available on acceptable terms or properly maintained/enforced by licensors, could prevent marketing or selling planned products.
• Sharing trade secrets with third parties increases the risk of competitors discovering them.
• Significant disruptions of information technology systems or security breaches could adversely affect the company's business.

Future Outlook

BetterLife Pharma expects to incur substantial and increasing losses for the foreseeable future as it researches, develops, and commercializes its products. The company intends to continue pursuing additional financing through equity or debenture issuances to fund operations and product development. The timing for BETR-002 and MM-003 INDs and clinical trials is currently under reassessment, with MM-003's path being re-evaluated due to the advent of effective SARS-CoV-2 vaccines. The company plans to file a new IND for MM-001 Phase 2b studies in the US using its own proprietary IFNa2b.

Management Comments

• "Our continued operations are dependent on our ability to generate future cash flows through additional financing or commercialization."
• "Management intends to continue to pursue additional financing through issuances of equity or debentures."
• "There is no assurance that additional funding will be available on a timely basis or on terms acceptable to us."
• "We expect to incur substantial and increasing losses for the foreseeable future as we research, develop and commercialize our products."
• "Capital markets continued to be challenging during fiscal 2025 for financings and, due to cash constraints experienced by the Company, it granted non-cash awards to key personnel and consultants to ensure retention of its human resources."
• "The Company intends to settle the judgment under terms agreeable by both parties." (referring to the Olymbec judgment)
• "Despite this material uncertainty, the Company concludes that it is appropriate to continue to adopt the going concern basis of accounting as the Company is confident, based on its financing history, debt settlements in the subsequent period, as well as additional planned measures, that sufficient funds will be forthcoming."

Industry Context

BetterLife Pharma operates in the highly speculative and capital-intensive biotechnology sector, focusing on neuro-psychiatric disorders and antiviral treatments. The development of non-hallucinogenic psychedelic derivatives (BETR-001) aligns with a growing interest in novel approaches to mental health treatment. The pursuit of interferon-based antivirals (MM-001, MM-003) reflects ongoing efforts to address infectious diseases, though the reassessment of MM-003's COVID-19 path highlights the rapid evolution of the vaccine landscape. The company's reliance on contract development and manufacturing organizations (CDMOs) is a common strategy for smaller biotechs to manage R&D costs and leverage specialized expertise.

Comparison to Industry Standards

• NA The document does not provide specific industry benchmarks or comparable companies/projects to assess the results against global standards. The company is pre-revenue and in early-stage development, making direct financial comparisons challenging without specific peer data.

Management Changes

Corporate Governance

Legal Proceedings

• A claim by a former chief executive officer for approximately $1 million in damages, share purchase options, and an order against further common share issuance was settled in December 2023 for $120,000, paid in 12 monthly installments from January 1, 2024 to December 1, 2024.
• A judicial demand by Olymbec Development Inc. against a former subsidiary (Pivot) and the company as guarantor resulted in a judgment on December 16, 2024, ordering the company to pay Olymbec $367,428 plus $15,000 in punitive damages. This judgment was registered in British Columbia on March 17, 2025, and the company intends to settle under agreeable terms.
• Lawsuits filed by a former director of MedMelior in New York State and US Federal Courts, seeking over US$2 million in compensatory and US$10 million in punitive damages, were dismissed in their entirety by both courts (December 2022 and November 2023, respectively). The former director allowed the federal appeal to lapse in November 2024, concluding the claims without payment or penalties against the company.
• A statement of claim for breach of a marketing contract filed against the company by a third party in January 2022 was settled for $30,000 in March 2023.
• MedMelior filed a notice of civil claim against its former pre-Amalgamation directors in British Columbia for breach of fiduciary and statutory duties and breach of contract, seeking general and special damages.

Related Party Transactions

• Key management compensation (salaries, consulting fees, directors fees, share-based payments) totaled $2,708,168 for the year ended January 31, 2025, with $1,679,378 being share-based payments.
• 1,700,000 stock options were granted to directors and officers in FY2025.
• 1,800,000 stock options were granted by MedMelior to directors and officers in FY2025.
• 4,875,000 Performance Stock Units (PSUs) were granted to directors and officers in FY2025.
• As of January 31, 2025, the company owed $1,476,700 to key management and directors, with $408,332 bearing 8% interest.
• Accrued advisory fees of $107,904 to directors (Mr. Metcalfe and Mr. Pullen) were forgiven in April 2024.
• The company issued convertible debentures totaling $100,000 to its Chief Executive Officer in March 2024.
• 500,000 common shares and 500,000 share purchase warrants were issued to the Chief Executive Officer for $50,000 in June 2024.
• $125,000 of convertible debentures issued to the CEO in December 2023 were converted into 1,250,000 common shares and warrants.
• $100,000 of convertible debentures issued to the CEO in March 2024 were converted into 1,000,000 common shares and warrants.
• Outstanding compensation to certain officers totaling $284,000 (including $84,000 from MedMelior) was settled through the issuance of 1,893,333 common shares of MedMelior in July 2024.
• In April 2025, outstanding compensation, accrued expenses, and accrued interest to Dr. Doroudian, Dr. Sheshbaradaran, and Ms. Ong totaling approximately $851,000 were settled with the issuance of 8,506,372 common shares.
• In April 2025, outstanding fees to Dr. Renz, Mr. Metcalfe, and Mr. Pullen totaling approximately $180,200 were settled with the issuance of 1,801,667 common shares.

Stakeholder Impact

• **Shareholders:** Face substantial risk of investment loss due to the company's going concern uncertainty, accumulated deficit, and continuous need for dilutive financing. Existing shareholders have experienced dilution from recent equity issuances and conversions of debentures and compensation. The penny stock classification further limits marketability.
• **Employees/Management:** Retention of key personnel is a concern, addressed by significant non-cash share-based payments due to cash constraints. Outstanding compensation to officers and directors has been settled through share issuances.
• **Creditors/Suppliers:** The company's working capital deficiency and aged accounts payables indicate potential challenges in meeting short-term obligations, with a contingent liability for potential interest or penalties on aged payables. Convertible debenture holders face conversion risk and potential dilution.
• **Customers:** As a pre-revenue, development-stage company, there are no current customers. Future customers would be impacted by the success or failure of product commercialization and regulatory approvals.

Next Steps

• Complete GMP manufacturing of BETR-001 oral capsules.
• Complete necessary preclinical and IND-enabling toxicology studies for BETR-001.
• Upon IND clearance for BETR-001, conduct a randomized placebo-controlled Phase 1A clinical trial in healthy volunteers.
• Follow Phase 1A with a randomized placebo-controlled Phase 1B-2 trial in patients with depression or anxiety disorders for BETR-001.
• Set up GMP manufacturing of BETR-002.
• Complete necessary preclinical and IND-enabling toxicology studies for BETR-002.
• Following BETR-002 IND, conduct a randomized placebo-controlled Phase 1 clinical trial in healthy volunteers.
• Follow Phase 1 with a randomized placebo-controlled Phase 2 trial treating benzodiazepine dependency for BETR-002.
• Complete development of the company's own patent-pending recombinant human IFNa2b for MM-001 and MM-003.
• File a new IND for MM-001 Phase 2b studies in the US using the company's own IFNa2b.
• Plan an inhalation GLP toxicology study in rats using MM-003 based on FDA feedback.
• Continue to pursue additional financing through issuances of equity or debentures.
• Obtain necessary external assistance to ensure accurate and timely performance of complex accounting issues to remediate material weakness in internal controls.
• Settle the judgment with Olymbec Development Inc. under agreeable terms.

Key Dates

Recommendation

Keywords

Biotechnology, Pharmaceuticals, Mental Disorders, Neuro-psychiatric, Antiviral, Drug Development, Clinical Trials, LSD Derivative, Dihydrohonokiol, Interferon-alpha 2b, HPV, Cervical Intraepithelial Neoplasia, COVID-19, SEC Filing, Going Concern, Biopharma, Preclinical, Clinical Stage, Intellectual Property